A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT07258511 · RECRUITING
Trial details
- NCT number
- NCT07258511
- Sponsor
- Janssen Research & Development, LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-04
- Primary completion
- 2028-12-12
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.